Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Update

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the target of a significant growth in short interest in August. As of August 31st, there was short interest totalling 523,200 shares, a growth of 241.1% from the August 15th total of 153,400 shares. Based on an average daily volume of 5,890,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 11.4% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, Maxim Group upgraded Virpax Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research note on Friday, July 19th.

Virpax Pharmaceuticals Stock Performance

Shares of NASDAQ VRPX traded down $0.02 during trading hours on Friday, reaching $0.83. The stock had a trading volume of 100,303 shares, compared to its average volume of 418,246. The business’s fifty day moving average is $1.09 and its two-hundred day moving average is $1.91. Virpax Pharmaceuticals has a twelve month low of $0.46 and a twelve month high of $9.00.

Virpax Pharmaceuticals (NASDAQ:VRPX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($1.75) earnings per share for the quarter.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.